Arellano and Lonial The success of cytokine therapy will likely depend upon deﬁning the most favorable combination of cytokines, the optimal site and route of administration, reaching a MRD status prior to cytokine therapy, and development of surrogate endpoints of anti-tumor activity that can be used to design subsequent clinical trials. Disclosures MA receives research support from Bayer Healthcare. SL has served as a consultant for, and received research support from, Berlex (now known as Bayer Healthcare). References Amsen D, Blander JM, Lee GR, et al. 2004. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell, 117:515–26. Arellano ML, Langston A, Winton E, et al. 2007. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant, 13 116–23. Arpinati M, Green CL, Heimfeld S, et al. 2000. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood, 95:2484–90. Balkwill F, Mantovani A. 2001. Inﬂammation and cancer: back to Virchow? Lancet, 357:539–45. Bancereau J, Steinman RM. 1998. Dendritic cells and the control of immu- nity. Nature, 392:245–52. Banchereau J, Briere F, Caux C, et al. 2000. Immunobiology of dendritic cells. Ann Rev Immunol, 18:767–811. Basak Saroj K, Harui A, Stolina M, et al. 2002. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macro- phage-colony-stimulating factor and interleukin-4. Blood, 99:2869–79. Bendandi M, Gocke CD, Kobrin CB, et al. 1999. Complete molecular remis- sions induced by patient-speciﬁc vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med, 5:1171–7. Bensinger WI, Martin PJ, Storer B, et al. 2001. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. [see comments]. N Engl J Med, 344:175–81. Berthier R, Martinon-Ego C, Laharie AM, et al. 2000. A two-step culture method starting with early growth factors permits enhanced produc- tion of functional dendritic cells from murine splenocytes. J Immunol Methods, 239:95–107. Borrello I and Pardoll D. 2002. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev, 13:185–93. Boyer MW, Waller EK, Bray RA, et al. 2000. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia, 14:412–8. Cashen AF, Link D, Devine S, et al. 2004. Cytokines and stem cell mobi- lization for autologous and allogeneic transplantation. Curr Hematol Rep, 3:406–12. Cassaday RD, Sondel PM, King DM, et al. 2007. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res, 13:540–9. Chow KU, Schneider B, Mitrou PS, et al. 2001. Inﬂuence of various cyto- kines on the expression of CD20 on the surface of CLL-cells in vitro. Leuk Res, 25:99–100. Coccia EM, Severa M, Giacomini E, et al. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol, 34:796–805. 24 Coppin C, Porzsolt F, Awa A, et al. 2005. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, CD001425. Correale P, Marsili S, Sabatino M, et al. 2005. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Oncol Rep, 13:751–6. Cortes J, Kantarjian H, O’brien S, et al. 1998. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia, 12:860–4. Cuenca A, Cheng F, Wang H, et al. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-speciﬁc t-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res, 63:9007–9015. Cvetkovic RS, Perry CM. 2006. Rituximab: a review of its use in non- Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs, 66:791–820. Davidson JA, Musk AW, Wood BR, et al. 1998. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother, 21:389–98. De Gast GC, Batchelor D, Kersten MJ, et al. 2003. Temozolomide fol- lowed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. British Journal of Cancer, 88:175–80. De Gast GC, Klumpen HJ, Vyth-Dreese FA, et al. 2000. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res, 6:1267–72. Dillon S, Agrawal A, Van Dyke T, et al. 2004. A toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal- regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol, 172:4733–43. Disis ML, Grabstein KH, Sleath PR, et al. 1999. Generation of immu- nity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res, 5:1289–1297. Dranoff G, Crawford AD, Sadelain M, et al. 1994. Involvement of granulo- cyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science, 264:713–6. Dranoff G, Jaffee E, Lazenby A, et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, speciﬁc, and long-lasting anti-tumor immunity. Proc Natl Acad Sci, USA, 90:3539–43. Eksioglu EA, Mahmood SS, Chang M, et al. 2007. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinﬂammatory response. Exp Hematol, 35:1163–71. Enzler T, Gillessen S, Manis JP, et al. 2003. Deﬁciencies of GM-CSF and interferon gamma link inﬂammation and cancer. J Exp Med, 197:1213–9. Fagnoni FF, Oliviero B, Giorgiani G, et al. 2004. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after alloge- neic myeloablative hematopoietic stem cell transplantation. Blood, 104:281–9. Fantuzzi G. 2003. Cytokine Knockouts. New Jersey: Humana Press. Fattorossi A, Battaglia A , Pierelli L, et al. 2001. Effects of granulocyte- colony-stimulating factor and granulocyte/macrophage-colony- stimulating factor administration on T-cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother, 49:641–8. Ferlazzo G, Klein J, Paliard X, et al. 2000. Dendritic cells generated from CD34+ progenitor cells with ﬂt3 ligand, c-kit ligand, GM-CSF, IL4, and TNF-alpha are functionalantigen-presneting cells resembling monocyte- derived dendritic cells. Journal of Immunotherapy, 23:48–58. Fonteneau JF, Gilliet M, Larsson M, et al. 2003. Activation of inﬂuenza virus-speciﬁc CD4+ and CD8+ T-cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood, 101:3520–3526. Biologics:Targets & Therapy 2008:2(1)